Ifinatamab Deruxtecan Granted Priority Review In The U.S. For Adult Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Who Experienced Disease Progression On Or After Platinum-Based Chemotherapy
14/04/2026 02:14
April 14 (Reuters) - Daiichi Sankyo Co Ltd 4568.T: DAIICHI SANKYO CO LTD: IFINATAMAB DERUXTECAN GRANTED PRIORITY REVIEW IN THE U.S. FOR ADULT PATIENTS WITH PREVIOUSLY TREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER WHO EXPERIENCED DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY Source text: [ID:] Further company coverage: 4568.T (Tokyo Newsroom)